To read the full story, subscribe or sign in.

Astellas’ zolbetuximab misses pancreatic cancer phase II endpoint

Oct. 14, 2025

Astellas Pharma Inc. reported Oct. 14 that its CLDN18.2-targeting monoclonal antibody, zolbetuximab (Vyloy), did not meet the primary endpoint of overall survival in the phase II Gleam trial of patients with advanced pancreatic cancer.

BioWorld BioWorld Asia Clinical Cancer Monoclonal antibody Asia-Pacific Japan

Today's news in brief

BioWorld

BioWorld briefs for Dec. 5, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 5, 2025.

Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift

BioWorld

Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...

Høeg appointment as acting CDER director tied to vaccine strategy?

BioWorld

After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...

Illustration of chromosome unraveling down to the DNA

First phase of synthetic human genome project successfully completes

BioWorld

The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...